Literature DB >> 28730869

Impact of iron deficiency on exercise capacity and outcome in heart failure with reduced, mid-range and preserved ejection fraction.

Pieter Martens1,2, Petra Nijst1,2, Frederik H Verbrugge1, Kevin Smeets1, Matthias Dupont1, Wilfried Mullens1,3.   

Abstract

BACKGROUND: Little information is available about the prevalence and impact on exercise capacity and outcome of iron deficiency in heart failure with mid-range (HFmrEF) and preserved (HFpEF) ejection fraction in comparison to heart failure with reduced ejection-fraction (HFrEF). Furthermore, no data is available about the progression of ID in patients without baseline anaemia.
METHODS: We evaluated baseline iron and haemoglobin-status in a single-centre, prospective heart failure database. Baseline functional status, VO2max, echocardiography and clinical-outcome (all-cause mortality and heart failure admissions) were evaluated. ID, anaemia, HFrEF, HFmrEF and HFpEF were defined according to established criteria.
RESULTS: A total of 1197 patients (71% male) were evaluated (HFrEF, n = 897; HFmrEF, n = 229; HFpEF, n = 72). The overall prevalence of ID was 53% (50% in HFrEF; 61% in HFmrEF; 64% in HFpEF) and 36% for anaemia. ID was associated with a lower VO2max in patients with HFrEF, HFmrEF and HFpEF (p < .001 in all). Iron status more closely related to a poor VO2max than anaemia status (p < .001). Furthermore, poor clinical-outcome was more strongly associated with iron status than anaemia status. Exposing eight patients without anaemia to iron deficiency for 39 months resulted in one patient developing new-onset anaemia (defined as progression of ID). Patients with progression of ID exhibited a significant higher risk of heart failure hospitalisation and all-cause mortality (HR = 1.4; CI = 1.01-1.94; p = .046) than patients without progression.
CONCLUSIONS: Iron deficiency is common in patients with HFrEF, HFmrEF and HFpEF, and negatively affects VO2max and clinical-outcome. Progression of iron deficiency parallels an increased risk for worsening of heart failure.

Entities:  

Keywords:  Iron deficiency; exercise capacity; heart failure; outcome

Mesh:

Substances:

Year:  2017        PMID: 28730869     DOI: 10.1080/00015385.2017.1351239

Source DB:  PubMed          Journal:  Acta Cardiol        ISSN: 0001-5385            Impact factor:   1.718


  37 in total

Review 1.  Anabolism to Catabolism: Serologic Clues to Nutritional Status in Heart Failure.

Authors:  Laura Murphy; Alastair Gray; Emer Joyce
Journal:  Curr Heart Fail Rep       Date:  2019-10

2.  Intravenous Iron-Carbohydrate Nanoparticles and Their Similars. What Do We Choose?

Authors:  Ana Maria Mehedinti; Cristina Capusa; Iuliana Andreiana; Gabriel Mircescu
Journal:  Maedica (Bucur)       Date:  2022-06

3.  Short-term treatment of iron deficiency anemia after cardiac surgery.

Authors:  Elio Venturini; Gabriella Iannuzzo; Anna DI Lorenzo; Gianluigi Cuomo; Andrea D'Angelo; Pasquale Merone; Giuseppe Cudemo; Mario Pacileo; Antonello D'Andrea; Carlo Vigorito; Francesco Giallauria
Journal:  Int J Cardiol Heart Vasc       Date:  2022-05-02

4.  Relationship of anemia and clinical outcome in heart failure patients with preserved versus reduced ejection fraction in a rural area of Thailand.

Authors:  Kittayaporn Chairat; Wipharak Rattanavipanon; Krittika Tanyasaensook; Busba Chindavijak; Suvatna Chulavatnatol; Surakit Nathisuwan
Journal:  Int J Cardiol Heart Vasc       Date:  2020-07-30

Review 5.  Iron Therapy in Heart Failure: Ready for Primetime?

Authors:  Ify R Mordi; Aaron Tee; Chim C Lang
Journal:  Card Fail Rev       Date:  2018-05

6.  How I treat anemia in heart failure.

Authors:  Inder Anand; Pankaj Gupta
Journal:  Blood       Date:  2020-08-13       Impact factor: 22.113

7.  A New View of Iron Management in Heart Failure: What Nephrologists Need to Know.

Authors:  Nupur N Uppal; Steven Fishbane
Journal:  Clin J Am Soc Nephrol       Date:  2021-03-29       Impact factor: 8.237

8.  Iron deficiency in pulmonary arterial hypertension: perspectives.

Authors:  Marceau Quatredeniers; David Montani; Alain Cohen-Solal; Frédéric Perros
Journal:  Pulm Circ       Date:  2021-06-14       Impact factor: 3.017

9.  Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: an overview.

Authors:  Marta Michalska-Kasiczak; Agata Bielecka-Dabrowa; Stephan von Haehling; Stefan D Anker; Jacek Rysz; Maciej Banach
Journal:  Arch Med Sci       Date:  2018-06-11       Impact factor: 3.318

10.  Iron Deficiency: Impact on Functional Capacity and Quality of Life in Heart Failure with Preserved Ejection Fraction.

Authors:  Alex Alcaide-Aldeano; Alberto Garay; Lídia Alcoberro; Santiago Jiménez-Marrero; Sergi Yun; Marta Tajes; Elena García-Romero; Carles Díez-López; José González-Costello; Gemma Mateus-Porta; Miguel Cainzos-Achirica; Cristina Enjuanes; Josep Comín-Colet; Pedro Moliner
Journal:  J Clin Med       Date:  2020-04-22       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.